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Executive summary 
Introduction 
 The main purpose of this capstone project is to provide an objective analysis of 
the cost of a medication error in the emergency department.  The secondary objective 
of this analysis is to estimate the cost avoidance impact of providing clinical pharmacy 
services in the emergency department (ED). 
Literature review 
 Previous literature has described the scope of clinical pharmacy services in the 
ED and has, to some extent, presented economic outcomes analyses of the impact of 
these services (Cohen et al., 2009; Lada and Delgado, 2007).  According to Cohen et 
al., the current literature is still lacking a formal pharmacoeconomic model for estimating 
cost avoidance associated with pharmacist-initiated interventions in the ED. 
Methods 
 Two data sets, one national and one local, were used to answer our basic 
research questions.  The Nationwide Emergency Department Sample (NEDS) was used 
to estimate the national median cost of a medication error in the ED, and intervention 
data from the ED at the University of Kentucky Chandler Medical Center (UKCMC) was 
used to estimate cost avoidance via the prevention of medication errors.   
Results 
 Based on analysis of the NEDS data, a medication error in the ED was estimated 
to result in a $268 increase in total ED costs.  The difference in the medication error 
group and the control group reached a high level of significance [p = 0.0000].  By 
applying this result to the data on interventions recorded in the ED at UKCMC, cost 
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avoidance attributable to the presence of a clinical pharmacist in the ED was estimated 
to be $189,208 per year.   
Discussion/Conclusion 
 The results of this analysis differ from those found in previous literature due in 
part to differences in methodology and population/facility size.  The results of this 
analysis suggest that the cost avoidance associated with the prevention of medication 
errors by a clinical pharmacist in the ED would cover a large portion of the expected 
salary and compensation associated with hiring a clinical pharmacist to work in the ED.   
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Introduction 
 The main purpose of this capstone project is to provide an objective analysis of 
the cost of a medication error in the ED.  The secondary objective of this analysis is to 
estimate the cost avoidance associated with the provision of clinical pharmacy services 
in the ED.  This capstone project begins with an examination of the past and current 
available literature relating to the provision of clinical pharmacy services in the ED, with 
emphasis placed on literature that addresses either the cost of medication errors or the 
economic impact of interventions made by pharmacists in the ED.  Where applicable, 
the literature review will expand to include more general research on economic 
outcomes as they relate to both the practice of pharmacy and medication errors. 
 After the pertinent literature has been reviewed and specific gaps in the current 
knowledge are identified, data and methods will be set up in a way to fill those gaps and 
answer the following basic research questions: 
(1) How much does a medication error increase total emergency department costs? 
(2) How much cost avoidance is associated with the prevention of medication errors by 
a clinical pharmacist in the emergency department?   
  Provided is a description of how two separate data sets, one containing national 
data and one containing local data, were employed to produce a cost avoidance 
estimate for clinical pharmacy services in the ED at UKCMC.  This section will also 
include a discussion of any potential ethical issues or possible sources of bias in 
collection and analysis of the data.     
 Immediately following the methods section, the analysis of the cost of a 
medication error in the ED will be presented.  That result will then be applied to the data 
obtained in the ED at UKCMC to estimate a cost avoidance value for the prevention of 
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medication errors by a clinical pharmacist in the ED.  In this section the inpatient costs 
for the medication error group and the control group will also be compared, and the 
effect of a medication error on the likelihood of being admitted to the hospital will be 
addressed.  
 Following the results section, a brief exploration of how these findings compare 
with the results of other researchers is offered.  The possible implications of these 
findings for hospital administrators as well as what other factors could enter into their 
decision-making process are discussed.  Finally, the conclusions reached through this 
analysis and possible arguments for ED policy changes will be presented.  This project 
concludes with the limitations of this research and author recommendations for further 
research in this field. 
Literature Review 
Past literature has described the scope of clinical pharmacy services in the ED.  
A recent review by Cohen, et al. listed more than fifty different services provided by 
clinical pharmacists in emergency departments.  Examples of these services included: 
conducting chart reviews, anticoagulation services, obtaining allergy histories, 
participating on medical rounds, prospective medication order review, and 
recommending dosage adjustments (Cohen et al., 2009).  In 2007, Lada and Delgado 
described additional pharmacy services in the ED such as answering nursing queries, 
obtaining order clarifications, and suggesting initiation/discontinuation of drug therapy.  
Many of these services could either directly or indirectly prevent or reduce the 
occurrence of medication errors and in effect reduce the number of preventable adverse 
drug events.   
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In light of the many available opportunities for provision of clinical pharmacy 
services in the ED, a survey of 135 physician residency programs in Emergency 
Medicine across the country was conducted in 2007 to assess the prevalence of these 
services in academic emergency departments (Szczesiul et al., 2009).  The 
investigators found that only 8% of institutions had 24-hour pharmacist coverage in the 
ED and 70% reported no pharmacy presence in the ED.  The authors also indicated that 
although approximately one third of academic EDs did have some form of clinical 
pharmacy presence, they did not appear to make full use of these clinical assets. The 
variety of clinical pharmacy service opportunities that exist in the ED directly reflects the 
complexity of care provided in the department.  This high stress, fast paced clinical 
environment coupled with the aforementioned complex level of care can lead to 
inadvertent mistakes in the medication use system.  Along with intensive care units and 
operating rooms, the ED is one of three places in the hospital with the highest frequency 
and severity of errors (Kohn et al., 1999) 
In December 2008, the American Society of Health-System Pharmacists (ASHP) 
released a statement regarding the provision of clinical pharmacy services in the 
hospital emergency department.  The conclusion of ASHP was that “Every pharmacy 
department should provide the ED with the pharmacy services required to ensure safe 
and effective patient care” (ASHP, 2008).  This statement reflects the values found in a 
1999 Institute of Medicine report on improving patient safety and applies those values to 
the practice of pharmacy in the ED (Kohn et al., 1999).  The ASHP proposed the need 
for further research in the field, including a focus on economic outcomes as they relate 
to pharmacy services in the ED. The current literature contains an assortment of 
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information on economic outcomes related to clinical pharmacists in other practice 
settings (Kaboli et al., 2006), but it is difficult to find information on economic outcomes 
research specific to prevention of medication error by a clinical pharmacist in the 
emergency department (Kroner et al., 2008; Lee et al., 2002; McMullin et al., 1999).  
Economic outcomes research in general allows policy makers to compare the cost of a 
proposed solution with the benefit offered by that solution.  Gaining the approval of 
hospital administration has been cited as the most common challenge to the 
implementation of ED pharmacy services (Witsil et al, 2010).   
In 2007, Lada and Delgado used pharmacists interventions at an urban, level I 
trauma center and applied them to an economic outcomes model based on 
pharmacists’ recommendations at a Veteran’s Affairs medical center to estimate cost 
avoidance associated with pharmacist interventions in the ED (Lee et al., 2002).  
According to the Centers for Disease Control and Prevention, “a trauma center is a type 
of hospital that has resources and equipment needed to help care for severely injured 
patients. The American College of Surgeons Committee on Trauma classifies trauma 
centers as Level I to Level IV. A Level I trauma center provides the highest level of 
trauma care” (CDC, 2009).  The analysis conducted by Lada and Delgado showed an 
estimated cost avoidance of approximately $3 million per year attributable to pharmacist 
interventions in the ED (Lada P, Delgado G, 2007).  In 1997, Bates et al. used billing 
data from two large tertiary care hospitals in Boston, Massachusetts to estimate the cost 
of a preventable adverse drug event (ADE).  They found that a preventable ADE in the 
hospital was associated with a post-event cost of about $4,685 and an increased length 
of stay of 4.6 days.   A recent review article examining the effect of clinical pharmacists 
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in the ED, however, stated “the cost avoidance data reported in the articles reviewed 
lack formal structured pharmacoeconomic analysis” (Cohen et al., 2009). In the 
discussion of their results, Lada and Delgado also identified development and validation 
of an economic model for evaluating ED pharmacy services as an area for future 
research (Lada P, Delgado G, 2007).  Thus, existing literature provides a fair foundation 
for estimating the cost of medication errors in the ED and the potential for cost 
avoidance associated with clinical pharmacy services in the ED, but further research is 
needed to develop an economic model to accurately describe the true value of clinical 
pharmacy services in the ED.  The knowledge gained by the following research may be 
considered as an essential piece of the economic architecture, which addresses the 
cost of medication errors in the ED and the potential for a clinical pharmacist to reduce 
these costs.    
Research Design 
Data Description 
 The 2006 Nationwide Emergency Department Sample (NEDS) is, as the name 
implies, a national database that contains data from 958 hospital-based EDs in 24 
states. In total the NEDS contains data for approximately 26 million records of ED visits, 
each of which are described by more than 100 possible data elements.   One of the 
elements included in this data set is a detailed list of any diagnosis codes from the 
International Classification of Diseases 9 - Clinical Modification (ICD 9-CM) that were 
recorded for each ED visit.  One important caveat of the NEDS data set is that is 
contains information on external causes of injury and poisoning.  This is represented by 
the variable “ECODES” in the NEDS.  The presence of this variable in the data set is 
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critical for performing the analyses required to answer the first research question above, 
because it allows the selection of a “medication error group” from the main data set.  A 
medication error group was selected by isolating ED visits that contained the ICD 9-CM 
error codes E850.0-E858.9.  These codes were chosen to identify the group with 
documented medication errors because they denote accidental poisoning by drugs, 
medicinal substances, and biologicals, but do not include poisonings secondary to 
suicide attempts or appropriate therapeutic administration of these compounds (ICD 9-
CM, E850.0-E858.9).  A more exhaustive description of the data elements contained in 
the NEDS is publicly available on the HCUP website (HCUP, 2006). 
Medication Error Cost Analysis 
Microsoft ® Structured Query Language (SQL) database management software 
was used to isolate emergency department events containing the ICD 9-CM medication 
error codes of interest from the general NEDS dataset.  With SQL, a file containing error 
code information, observation weighting values, and ED cost information along with 
unique identifiers for each observation in the data set was formatted for analysis using 
the statistics software STATA (StataCorp, 2007, College Station, TX, USA), where all 
further data analysis was carried out.  Again, using SQL, a control group was randomly 
selected from those observations not containing the medication error codes E850.0-
E858.9 at a control: case ratio of more than 2:1. There were two reasons for doing this.  
First, because of the size of the existing data set, no additional costs were incurred by 
increasing the number of controls.  Second and more importantly, as the ratio of 
controls to cases increases, the power of the study also increases up to a control-to-
case ratio of about 4:1 (Hennekens and Buring, 1987).   
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Because it is known that medical cost data is skewed to the right and non-
normally distributed, STATA was used to generate transformed cost data histograms for 
total ED costs in both the medication error group and the control group.  Some scholars 
in the past have argued against transformation analysis for non-normal data, but in this 
case it is being used as an empirical check for skewed data rather than to represent 
quantitative findings (Nixon and Thompson, 2004).   
Determining the cost of medication errors was conducted using median costs 
because of the non-normal distribution of data.  The Wilcoxon rank sum test was used 
to detect any significant differences in median costs between the medication error group 
and the control group.    
 In the NEDS, inpatient cost information for ED events that resulted in admission 
to the hospital was provided in a separate database known as the inpatient file.  
Observations in the inpatient file were linked back to the core emergency department 
file by a unique identification variable.  This unique identification variable allowed for the 
generation of two additional data sets, one containing cost information on patients from 
the original medication error group who were also admitted to the hospital, and the other 
containing cost information on patients from the original control group who were also 
admitted to the hospital.   Median inpatient cost data was computed and Wilcoxon rank 
sum tests were performed on the inpatient cost data using the same methods described 
for the ED cost data.  Analyses were also conducted to determine what impact a 
medication error in the ED had on the likelihood of being admitted to the hospital from 
the ED. 
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Cost Savings/Avoidance Analysis 
To determine cost savings, data compiled between September 2008 and 
February 2009 in the ED at the University of Kentucky Chandler Medical Center 
(UKCMC) was used.  Reportable events (medication errors) that occurred in the ED 
were recorded using an online form. This form allowed the user to input several 
variables to describe each event.  These descriptive variables contained information on 
date and time of each event, what medication was involved, what type of practitioner 
reported the event, and what intervention was made.  A potential severity score was 
also assigned to each event, ranging from A to E, with A being the least serious and E 
being a potentially severe or life-threatening error.  To estimate cost savings generated 
via the avoidance of preventable medication errors by a clinically trained ED 
pharmacist, this data was used to determine the number and percentage of medication 
errors prevented by interventions attributable to the presence of a pharmacist in the ED.  
The cost data generated from the NEDS database was then used to calculate a cost 
avoidance estimate for the prevention of medication errors by a pharmacist in a hospital 
based ED. 
 
Potential Ethical Problems 
 
As in any analysis, there is a possibility of researcher bias in the collection and 
collation of data.  To minimize this possibility, a non-practicing health services 
researcher was consulted to assist in the compilation and analysis of available data.  
Medication error reporting is an interesting subject as it relates to bias, because many 
individual factors can lead to either over reporting or under reporting of errors.  Due to 
the nature of the data collected in the ED at UKCMC, attention bias could have led to a 
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relative over reporting of medication errors.  For example, a pharmacist who is specially 
trained to recognize and respond to medication therapy issues may be more attuned to 
the recognition of medication errors than another member of the healthcare team whose 
training and focus is not as heavily oriented toward drug therapy.  For this reason, given 
the same set of patient encounters, a pharmacist would be likely to report a higher 
number of medication errors even though the true number of errors would be the same 
for both situations.  A publicly available national database was used to ensure that no 
differential reclassification occurred favoring pharmacy services.  Although the NEDS is 
a national data set, over or under reporting of the error codes of interest could have 
occurred.  Bias leading to under reporting of errors in the NEDS could stem from an 
overarching culture in which medication error reporting leads to punishment for 
individuals rather than being used as a learning tool to improve the local healthcare 
process. One author suggested moving away from this culture of blame and punishment 
toward a “culture of safety”, where reporting errors and learning from them are 
emphasized as a method of achieving safe health care (Leape, 2009).  Until this type of 
culture is in place, however, one might expect the status quo of medication error under 
reporting to persist. 
Results 
From the NEDS database the medication error group was found to contain a total 
of 59,633 observations.  Again using SQL, a control group of size n=150,000 was 
selected from those observations not containing an ICD 9- CM error code between 
E850.0-E858.9. This selection yielded a control: case ratio of roughly 2.5:1.  
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As shown in Figure 1, transformation modeling conducted in STATA confirmed 
that total ED costs for both the medication error group and the control group fit well into 
a logarithmic model. 
Figure 1. Transformation analysis performed to determine appropriate method of 
normalization of cost data. 
Case costs     Control costs 
  
______________________________________________________________________ 
 
 
 
Emergency Department Cost Analysis 
Of the 59,633 observations in which a medication error of E850.0-E858.9 was 
documented, 44,439 also contained a value for total ED costs for the visit.  Table 1 
below contains the breakdown of ED cost data for both the medication error group and 
the control group.  A Wilcoxon rank sum test showed that the difference in total 
emergency department costs between these two groups reached a high level of 
significance [p = 0.0000].  
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Table 1: ED cost data for medication error group and control group 
 Medication Error Group Control Group 
Difference  
(95% CI) 
Median ($) 1027 759 268 
Interquartile     
Range ($) 513-1922 376-1518  
Range ($) 25-32,753 25-45752  
 
Inpatient Cost Analysis 
 From the original medication error group of 59,633 observations, 19,834 were 
present in the inpatient database showing that they had been admitted.  Only 260 of 
these observations were missing total cost information. Of the other 19,574 
observations, the median total cost for emergency department and inpatient services 
was $11,836.  Of the 150,000 observations in the control group, 23,002 were present in 
the inpatient database.  The median for the 22,694 observations in the control group 
that contained total cost information for emergency department and inpatient services 
was $16,102.  A Wilcoxon rank sum test showed that the difference in total hospital 
costs (ED plus inpatient) between these two groups also reached a high level of 
significance [p = 0.0000].  
Table 2: Inpatient Admissions stratified by group 
 Medication Error Group Control Group 
Admitted 19,834 23,002 
Not Admitted 39,799 126,998 
Odds ratio 2.75  
  
 Patients who experienced a medication error were more likely to be admitted to the 
hospital than those who did not. OR = 2.75 (95% confidence interval = 2.69-2.81). 
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UKCMC ED Data Analysis 
Table 3: UKCMC ED Reportables September 08-February 09 
Person Reporting 
Error/Intervention 
Number of Errors/Interventions 
Reported 
Percentage of 
total 
PharmD 277 74.5% 
PharmD Resident 50 13.4% 
PharmD Student 25 6.7% 
Nurse 15 4.0% 
PharmD/Nurse 1 0.3% 
Pharmacy Technician 4 1.1% 
Total 372 100.0% 
   
Attributable to ED 
Pharmacist Presence 353 94.9% 
 
The data from the ED at the UKCMC showed that during the six-month period of 
September 2008 to February 2009, 353(94.9%) reported interventions were attributable 
to the presence of a clinical pharmacist in the ED (Table 3).  By applying this number of 
interventions to the calculated estimate of the cost of a medication error in the ED, a 
cost avoidance figure was determined by the following: 
 
(Number of Interventions) x (Median Cost of Medication Error) = Cost Avoidance 
(353) x ($268) = $94,604 
 
 This cost avoidance figure is based on interventions made over a six month 
period.  By extrapolating this figure out to a one-year period, one could expect the cost 
avoidance total to double to roughly $189,208.  
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Discussion 
 The primary goal of this project was to determine the cost of a preventable 
medication error in a hospital emergency department using an unbiased national data 
set.  Our analysis of the data showed that a preventable medication error results in a 
median increase in ED costs of $268.   
 The secondary goal was to estimate the economic impact of interventions made 
by a clinical pharmacist in the ED by looking specifically at cost avoidance secondary to 
the prevention of medication errors in the ED.  At UKCMC, in a six-month period, the 
data shows that 353 medication errors were prevented by interventions initiated by a 
clinical pharmacist in the ED.  This number included not only interventions made by the 
clinical ED pharmacist, but also those made by the PharmD candidates and pharmacy 
practice residents they were responsible for precepting.  The presence of PharmD 
candidates and pharmacy practice residents in the ED was determined to be directly 
dependent on the fact that there was a clinical ED specialist there to supervise and 
mentor them, and therefore any interventions they made could be causally linked back 
to the ED pharmacist.  Based on the number of interventions recorded in this six-month 
window and the previously estimated ED cost of a preventable medication error, the 
associated cost avoidance for these interventions is $94,604 over six months or about 
$189,208 per year.  This estimated cost avoidance may be sufficient to cover a large 
portion of the expense associated with financing two clinical ED pharmacist positions at 
UKCMC.  
 Characteristics of an ideal ED clinical pharmacist would be one that has (A) 
graduated from a college of pharmacy accredited by the Accreditation Council for 
Pharmacy Education (ACPE) and (B) completed two years of post-graduate residency 
	   18	  
training, with the second year focusing on Emergency Department pharmacy practice.  
Because of the scarcity of post-graduate year two (PGY2) ED pharmacy practice 
residency programs, a pharmacist with at least three to five years of clinical practice 
should also be able to take on this role.    
 According to the Bureau of Labor Statistics (BLS), the mean national salary for 
pharmacists working in general medical and surgical hospitals was $103,480 (BLS, 
2008).  Based on the expected level of experience and training required for becoming a 
clinical ED pharmacist, hospital administrators can expect to pay this amount ±10%.  
This salary will vary with level of pharmacist experience and regional differences in 
variables such as demand for pharmacists and cost of living.  Assuming a generous 
benefits package valued at roughly 40% of base salary, the true cost of hiring a full time 
clinical pharmacist for the ED would be roughly $145,000 per year.  
The ED at UKCMC has a patient volume of roughly 50,000 visits per year.  
During the time this medication error intervention data was collected, two clinical ED 
pharmacists were employed at UKCMC, providing services to the ED ten hours per day, 
seven days per week.  The pharmacists were scheduled to work between 1pm and 
11pm.  This time frame overlaps significantly with the hours of 3pm to 2am, which are 
reported to be the busiest hours of the day in the ED at UKCMC.  It is expected that the 
true cost avoidance figure would vary by facility depending on the level of pharmacist 
presence in the ED (hours/week) and the annual number of patients treated at a given 
ED. 
 Lada and Delgado reported a cost avoidance from prevention of med errors of 
$436,150 over four months (Lada P, Delgado G, 2007).  There are a few reasons for the 
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difference between their reported cost avoidance and ours.  First, the setting of their 
study was the Emergency Department at Detroit Receiving Hospital in Detroit, Michigan, 
whose annual patient volume (84,000/year) is nearly twice that of the ED at UKCMC.  
Other differences may stem from the provision of 24-hour pharmacist coverage in the 
ED and the fact that they based cost estimates on expert’s projections of the costs of 
treating the potential medication errors that their pharmacists prevented.  
 Compared to research on preventable adverse drug events in the hospital, which 
estimated hospital costs at $4,685 (Bates, 1997), our findings for a preventable 
medication error in the ED suggest a much smaller increase in costs.  This may be 
related to the dramatic increase in the acuity of care for inpatients when compared to 
ED patients.  One might expect that a medication error occurring in a patient who is 
already in need of admission to the hospital would require more money and resources 
to remedy.   
 Though the total inpatient costs were higher for patients who were admitted to 
the hospital without experiencing a medication error in the ED, our analysis showed that 
patients who experienced a medication error were almost three times as likely [OR = 
2.75 (2.69-2.81)] to require hospital admission.  This finding implies that medication 
error prevention by a clinical ED pharmacist could further contribute to cost avoidance 
by preventing this increase in the patient’s likelihood of being admitted to the hospital 
and incurring inpatient medical costs. 
 One could argue that patients who are more seriously ill and require a more 
complex level of care would logically be more likely to experience a medication error 
and subsequently be admitted to the hospital.  This analysis was not set up to assess 
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severity of illness or required level of care. By using total hospital costs (inpatient plus 
ED) as a surrogate for severity of illness, however, it appears that the patients who were 
admitted from the ED without experiencing a medication error were actually more 
expensive to care for and, by extension, more severely ill.   
Litigation costs represent an immense area of potential cost avoidance not 
addressed in this research.  A 2002 report on medical malpractice claims in The 
Archives of Internal Medicine stated that preventable inpatient ADEs (medication errors) 
had a mean cost per case of $376,500 for defense and indemnity (Rothschild, 2002).  In 
September of 2008, Medicare stopped paying for certain types of medical errors known 
as “never events” that had been identified previously by the National Quality Forum 
(Milstein, 2009).  While medication errors were not included as one of these never 
events, the National Quality Forum (NQF) did include “patient death or serious disability 
associated with a medication error” as a serious reportable event in an updated 
consensus report (NQF, 2006).  As healthcare costs and public demand for higher 
quality healthcare continue to increase, it is logical to believe that Medicare could in the 
near future add some medication errors to the list of never events that will no longer be 
covered. 
Limitations of Analysis 
All studies have limitations in their analyses; some limitations have also been 
identified in this study.  One limitation of this analysis is that the total cost avoidance 
estimates are only valid for the ED at UKCMC, because the intervention data collected 
there was essential in the cost avoidance calculation.  On the other hand, since the 
estimated cost of a medication error in the ED is based on national median data from 
NEDS, this figure should be applicable to the wider population of other hospital-based 
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emergency departments.  Hospital administrators at other facilities could possibly use 
this information and apply it to their own data on medication errors, thus giving them 
some guidance on local policy implementation pertaining to clinical ED pharmacy 
practice.   
As stated earlier in the research design, the events in the ED at UKCMC were 
assigned a subjective potential severity rating by the person reporting the event.  While 
subjective in nature, this variable suggests the common sense notion that medication 
errors that differ in severity will require different treatments that will vary in cost.  Our 
analysis is based on the assumption that regardless of the potential severity of an 
individual event, in aggregate the associated cost should approach the same value.  
This assumption allows the possibility of either over or under estimating the true cost 
avoidance figure.      
Further Research 
      Ongoing research in this field should expand the assessment of cost 
avoidance to include other areas of pharmacy practice in the ED.  Examples could 
include: therapeutic drug substitution, drug selection and dosing, patient and family 
medication counseling, and home medication reconciliation.  Other ancillary services 
provided by a clinical pharmacist in the ED including answering medication questions 
posed by other healthcare practitioners and precepting pharmacy students and 
residents should also be studied.    
The current analysis could be expanded to include a subgroup analysis designed 
to detect significant differences in costs of medication errors associated with specific 
drugs or drug classes (i.e. vancomycin or antimicrobial agents).  Such an analysis could 
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help guide ED practitioners and administrators in the development of policies and 
procedures directing at reducing medication errors in these areas.  
            
Conclusion 
 Based on the analysis of the data from NEDS 2006, a medication error in the ED 
results in an increase of $268 in total ED costs alone.  When this figure is coupled with 
data from UKCMC dealing with pharmacist-led interventions to prevent medication 
errors, six-month cost avoidance totals come to $94,604.  Based on national averages, 
this amount is enough to pay for a fair portion of the salary for the two clinical ED 
pharmacists employed by UKCMC during that time period.  Given that this cost 
avoidance figure takes into account neither the avoidance of litigation and indemnity 
costs or the cost savings created by other functions of a clinical ED pharmacist, we 
conclude that a clinical pharmacist in the ED may generate enough cost avoidance to 
justify a significant portion of the monetary cost of his or her salary and other 
compensation. 
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